Details for 2020800617

Up to date per 01.04.2026

Actions

Title / Product Name

THERAPEUTISCHE KOMBINATIONEN VON ACALABRUTINIB UND CAPIVASERTIB ZUR BEHANDLUNG VON B-ZELL-MALIGNITÄTEN

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2020800617

EP Publication Number

4054582

E-Number

1832170

Language

PCT Number

EP20080493

Publication Date

14.09.2022 A

03.09.2025 B1

Registration Date

03.09.2025

AT Publication Date

15.09.2025

Application Date

30.10.2020

Registration Number

Priorities

04.11.2019

201962930208 P

IPC

A61K 31/4985 20060101AFI20210514BHEP

Maximum Duration of Protection

30.10.2040

Owner

Astrazeneca AB 151 85 SödertäljeSE

Representative

Paul CosmoviciGumpendorfer Straße 1421060 WienAT

Inventor

DRY, HannahAstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437 Wilmington, Delaware 19850-5437US

WILLIS, BrandonAstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437 Wilmington, Delaware 19850-5437US

BLOECHER, AndrewAstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437 Wilmington, Delaware 19850-5437US

METTETAL, JeromeAstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437 Wilmington, Delaware 19850-5437US

Information about Fees